A Solid Summary on the Latest MPN Research in 2017 Drs. Joseph R. Mikhael and Ruben A. Mesa analyze and discuss pertinent clinical studies and late breaking updates pertaining to the care of patients with chronic myelogenous leukemia (CML) and myeloproliferative neoplasms (MPN) in this Best of the Day discussion from the annual hematology meeting […]
Long Term Exposure to Radiation puts you at higher risk for MPN The Savannah River Site is on a list of qualified places for Special Exposure Cohort Employees (SEC) The SEC allows eligible claimants to be compensated without the completion of a NIOSH radiation dose reconstruction or determination of the probability of causation. To qualify […]
A survey is being conducted to learn more about the most common symptoms experienced by ET patients, and how these symptoms affect the lives of patients. This information may help improve how the patient’s experience is accounted for in clinical trials that measure the effect of treatments. The study is being conducted by Quintiles IMS […]
New Leukemia Research in Phase I/IIa Clinical Trial Biosight, an Israeli pharmaceutical development company that is working on a cure for leukemia, this week closed an investment of $13 million led by pharmaceutical investment firm Arkin Holdings, run by pharma mogul Mori Arkin, and US-based venture firm Primera Capital. The money will be used to […]
“Researchers found that the mean hemoglobin and hematocrit levels of the polycythemia vera group were 16.7 g/dL and 50.4%, respectively, vs 13.4 g/dL and 40.3% in control arm. These differences were not statistically significant.” …these differences look very statistically significant to me! (comment added by MPN-CC) “Results showed that patients with polycythemia vera had a […]
Key points The novel IFNα-2b AOP2014 administered once every two weeks (or once a month) has low toxicity and induces high and sustained response rates in PV patients. AOP2014 induces significant partial and complete molecular response rates, as reflected by reduction of JAK2 allelic burden Click here for the complete article Details on the clinical trial […]
THE STORY OF JAK2 Four teams race to find the mysterious cause of a group of blood cancers. JAK2 MUTATIONS AT A GLANCE Involved in: blood cancers and disorders including polycythemia vera, primary myelofibrosis, thrombocythemia, leukemia. Testing requires: a blood draw. Bone marrow samples occasionally used. Prognosis: Patients with a JAK2 mutation have a lower […]
J Korean Med Sci. 2016 Oct;31(10):1579-1585. English. Published online Jul 22, 2016. http://dx.doi.org/10.3346/jkms.2016.31.10.1579 © 2016 The Korean Academy of Medical Sciences. Incidence, Survival and Prevalence Statistics of Classical Myeloproliferative Neoplasm in Korea Yoojoo Lim, Jeong-Ok Lee and Soo-Mee Bang Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea. Address for Correspondence: Soo-Mee Bang, MD. […]
Scientists have devised a way to destroy blood stem cells in mice without using chemotherapy or radiotherapy, both of which have toxic side effects. Blood stem cell transplantation, widely known as bone marrow transplantation, is a powerful technique that potentially can provide a lifelong cure for a variety of diseases. But the procedure is so […]
Conclusions: MPN patients are understudied and there are currently no studies that have explored the effects of physical activity on sympton burden and QoL in these patients. There is some evidence demonstrating the efficacy of physical activity for improving a variety of outcomes in specific hematological cancer subtypes. Because of preliminary evidence suggesting a positive […]
Site by: Kaleidoscopic
